Markets:

Overview

News

Currencies

International

Treasuries

Bayer Ag Ord (OP:BAYZF)

38.70 -1.09 (-2.74%)

Streaming Delayed Price Updated: 2:54 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag Ord

< Previous 1 2 3 Next >

Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor ↗

October 05, 2022

Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup...

Via Benzinga

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report ↗

September 14, 2022

Via Benzinga

Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug ↗

September 08, 2022

Via Benzinga

Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death ↗

August 29, 2022

Via Benzinga

FDA Approves Expanded Use For Bayer's Prostate Cancer Drug ↗

August 08, 2022

Via Benzinga

Morning Brief: Top Financial Stories Dominating on Friday, June 10 ↗

June 10, 2022

Reuters Rebranded McDonald’s Restaurants To Reopen In Russia

Via Benzinga

US Top Court To Decide On Bayer's Roundup Weedkiller Appeal ↗

June 10, 2022

Via Benzinga

Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara ↗

May 20, 2022

Via Benzinga

FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗

April 21, 2022

The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.

Via Benzinga

Eli Lilly To Suspend Sale Of 'Non-Essential' Medicines To Russia ↗

March 15, 2022

Eli Lilly And Co (NYSE: LLY) said it would continue to supply drugs to Russia for urgent medical conditions such as cancer and diabetes but will suspend sales of "non-essential medicines."

Via Benzinga

Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy ↗

March 15, 2022

Exelixis Inc (NASDAQ: EXEL) announced results from the final analysis of the second primary endpoint of overall survival (OS) from the phase 3 COSMIC-312 trial of Cabometyx (cabozantinib) plus...

Via Benzinga

Recursion, Bayer Expand Fibrosis Pact To Include Inferential Search Capabilities ↗

December 06, 2021

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) expanded its existing strategic collaboration in fibrosis with Bayer AG (OTC: BAYRY). The expanded...

Via Benzinga

Bayer's Nubeqa Shows Prolonged Survival In Late-Stage Prostate Cancer Trial ↗

December 03, 2021

Bayer AG (OTC: BAYRY) said a combination therapy, including its Nubeqa drug, was shown to prolong the lives of men who have metastatic prostate cancer in a clinical...

Via Benzinga

Microsoft, Bayer Collaborate To Develop Digital Agricultural Tools, Capabilities ↗

November 17, 2021

Microsoft Corp (NASDAQ: MSFT) and Bayer AG (OTC: BAYRY) (OTC: BAYZF) collaborated on new internet-based products aimed at helping farmers and industries...

Via Benzinga

Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration ↗

August 24, 2021

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related...

Via Benzinga

Berkeley Lights, Bayer Ink Discovery Pact For Next-Gen Traits In Agricultural Sector, Berkeley Q2 Earnings Miss Estimates ↗

August 11, 2021

Berkeley Lights Inc (NASDAQ: BLI) reports Q2 sales of $19.3 million, +82% Y/Y, but slightly missing the consensus of $19.64 million. The Company expanded the installed...

Via Benzinga

Topics Earnings

Merck - Bayer's Heart Failure Treatment, Verquvo Scores European Nod ↗

July 21, 2021

The European Commission (EC) has approved Merck & Co Inc's (NYSE: MRK) soluble guanylate cyclase (sGC) stimulator Verquvo (vericiguat). Verquvo...

Via Benzinga

Bayer's Kerendia Scores Long-Awaited Kidney & Heart Disease Nod For Type 2 Diabetes ↗

July 12, 2021

The FDA on Friday approved Bayer AG's (OTC: BAYRY) chronic kidney disease (CKD) drug Kerendia (finerenone), the first and only nonsteroidal mineralocorticoid...

Via Benzinga

Why Did Novocure Shares Plunge Today? ↗

July 01, 2021

Novocure Ltd (NASDAQ: NVCR) has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields (TTFields) together with Bayer...

Via Benzinga

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials ↗

June 08, 2021

Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative...

Via Benzinga

Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals ↗

June 03, 2021

Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline...

Via Benzinga

Bayer Mulls Ending US Retail Sales Of Weedkiller Glyphosate: Reuters ↗

May 27, 2021

A U.S. judge rejected Bayer AG’s (OTC: BAYRY) plan to try and limit the cost of future class action claims that its Roundup weedkiller causes cancer, saying that...

Via Benzinga

Artificial Intelligence Doctor App Ada Health Closes $90M Funding Led By Bayer, Samsung ↗

May 27, 2021

German digital health firm Ada Health has raised a $90 million funding round at an undisclosed valuation bringing total investment in the company up to around $150...

Via Benzinga

Topics Artificial Intelligence

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.